UPDATE: Click here to order samples for your practice.

POWERED FOR PENETRATION

  • An advanced QD formulation designed to facilitate corneal penetration while maintaining ocular comfort1,2

POWERED FOR EFFICACY

  • Proven QD efficacy at a low concentration1,3,4
  • PROLENSA® delivers consistent potency every drop, every time, with no shaking required1

POWERED FOR OCULAR COMFORT

  • PROLENSA® patients reported less foreign body sensation, photophobia, and redness vs vehicle5
  • Formulated to be close to the physiological pH of natural tears, with a pH of 7.81

POWERED FOR PATIENTS

  • Bausch + Lomb is committed to providing access to PROLENSA® for your eligible patients whether they are eligible insured, eligible uninsured, or on Medicare Part D

PROLENSA® is manufactured in an FDA-approved facility that helps ensure stringent safety and quality control

Indications and usage

PROLENSA® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Important Safety Information

  • PROLENSA® contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.
  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
  • PROLENSA® should not be instilled while wearing contact lenses. The preservative in PROLENSA®, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA®.
  • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Click here for full Prescribing Information for PROLENSA®.

References: 1. PROLENSA Prescribing Information. 2. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. 3. Silverstein SM, Jackson MA, Goldberg DF, Muñoz M. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery. Clin Ophthalmol. 2014;8:965-972. 4. Walters TR, Goldberg DF, Peace JH, Gow JA; for the Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014;121(1):25-33. 5. Data on file, Bausch & Lomb Incorporated.

© 2021 Bausch & Lomb Incorporated or its affiliates. All rights reserved. PRA.0054.USA.21

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION